FSE

Kings Entertainment & Braight AI Entering Underbanked LATAM Market with Proprietary Risk Scoring Solution: AI Risk Credit

Retrieved on: 
Thursday, August 31, 2023
CSE, FSE, Gold, Risk, Artificial intelligence, Big data, Kings Entertainment Company, LATAM, Bank

With 70% of the LATAM's population of 400 million being unbanked or underbanked, Braight's AI Risk Credit technology offers a timely solution that enables financial institutions to assess the creditworthiness of millions of people currently excluded from the consumer finance market.

Key Points: 
  • With 70% of the LATAM's population of 400 million being unbanked or underbanked, Braight's AI Risk Credit technology offers a timely solution that enables financial institutions to assess the creditworthiness of millions of people currently excluded from the consumer finance market.
  • "The timing couldn't be better for entering LATAM's extremely large market," said Braight CEO Maciej Jarząb.
  • Braight's AI Risk Credit technology generates score and credit recommendations based on customers' online behavior, which increases the accuracy of current credit decision making processes.
  • Testing has confirmed the AI Risk Credit algorithm provides 95% accuracy in predicting borrowers' financial behaviors.

MediPharm Labs Publishes Study Investigating Medical Cannabis Impacts on Anxiety and Depression Outcomes in Fibromyalgia Patients

Retrieved on: 
Thursday, August 31, 2023
Depression, Education, Placebo, FSE, Insomnia, American Journal, Patient, CBD, Cannabis, TSX, Chronic pain, Fatigue, Medical device, Nursing, Pharmaceutical industry, Anxiety, Fibromyalgia

Between baseline and follow-up appointments, 75% of patients saw a significant decrease in their self-reported illness severity and the study reported reductions in depression and anxiety scores.

Key Points: 
  • Between baseline and follow-up appointments, 75% of patients saw a significant decrease in their self-reported illness severity and the study reported reductions in depression and anxiety scores.
  • The study data shows that medical cannabis may play an effective role in the management of fibromyalgia and associated symptoms of depression and anxiety.
  • Harvest Medicine Inc. ("Harvest Medicine" or "HMED") includes a medical clinic network, and is a wholly owned subsidiary of MediPharm Labs.
  • Anxiety scores were improved in 22% of those patients reporting mild-moderate severity, and in 48% of patients reporting severe anxiety.

Appia Deploys Third Drill at PCH Ionic Clay Project in Brazil

Retrieved on: 
Thursday, August 31, 2023
Diamond, Vendor, REE, CSE, University, API, Season, Auger, Magnetic anomaly, Tropical climate, FSE, IP, Brazilian, Fission Uranium Corp., National instrument, National Instrument 43-101, Rare-earth element, News, Niobium, Appia

Toronto, Ontario--(Newsfile Corp. - August 31, 2023) - Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF) (FSE: A0I0) (the "Company" or "Appia") Appia is pleased to announce the deployment of a third drill on-site to investigate a significant geophysical anomaly at depth below Target IV at Appia's PCH Ionic Adsorption Clay Project, Goias State, Brazil.

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - August 31, 2023) - Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF) (FSE: A0I0) (the "Company" or "Appia") Appia is pleased to announce the deployment of a third drill on-site to investigate a significant geophysical anomaly at depth below Target IV at Appia's PCH Ionic Adsorption Clay Project, Goias State, Brazil.
  • Appia is currently using three (3) drills - one RC, one Auger, and one Diamond drill.
  • The initial target will be drilled to 250 metres depth to test both the ionic clay and hardrock mineralization below Appia's priority ionic clay structures which reach an average depth from surface of +/- 12 metres.
  • The PCH Project is 17,551.07 ha in size and located within the Goiás State of Brazil.

Otsuka Pharmaceutical to Acquire Mindset Pharma

Retrieved on: 
Thursday, August 31, 2023
Agreement, Minority, Canadian House of Commons Special Committee on Electoral Reform, CSE, MSET, OAI, Committee, CAD, Arrangement, FSE, IP, Antipsychotic, DSM-IV codes, Good, Acquisition, VWAP, Patient, Transaction, Supreme court, Otsuka Pharmaceutical, Law of the United Kingdom, Multilateral, Psychiatry, Neurology, Pharmaceutical industry, Security (finance), Mindset

Under the terms and conditions of the Agreement, each Mindset shareholder will receive $0.75 in cash for each share of Mindset held.

Key Points: 
  • Under the terms and conditions of the Agreement, each Mindset shareholder will receive $0.75 in cash for each share of Mindset held.
  • Makoto Inoue, president and representative director of Otsuka, commented, "Otsuka Pharmaceutical has designated psychiatry and neurology as one of its top priority therapeutic areas and has been developing antipsychotic agents with clinical significance on a global basis.
  • James Lanthier, CEO of Mindset, said, "We are thrilled to announce this all-cash transaction with Otsuka as we believe it maximizes value and is a great outcome for all Mindset stakeholders.
  • We believe Otsuka is ideally positioned to maximize the value of the Mindset assets and IP portfolio to the future benefit of patients."

PreveCeutical Engages New to the Street for Production & Broadcasting Services

Retrieved on: 
Thursday, August 31, 2023
Agreement, CSE, Special, FSE, CBS, NBC, Upper Street (group), Suite, Client, Bloomberg, Good, ABC, Fox Business, The Company, News, Television, Mobile phone, Newsmax, USD

VANCOUVER, BC, Aug. 31, 2023 /PRNewswire/ - PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), announces that it has entered into a Service Agreement dated effective September 1, 2023 (the "Agreement") with New to the Street Group LLC ("NTTS"), whereby NTTS will provide production and broadcasting services (the "Services") to the Company involving television, production, media analysis, and procurement.

Key Points: 
  • VANCOUVER, BC, Aug. 31, 2023 /PRNewswire/ - PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), announces that it has entered into a Service Agreement dated effective September 1, 2023 (the "Agreement") with New to the Street Group LLC ("NTTS"), whereby NTTS will provide production and broadcasting services (the "Services") to the Company involving television, production, media analysis, and procurement.
  • NTTS has agreed to accept the following compensation in exchange for performing the Services: The Client agrees to pay New to the Street Group LLC $150,000.00 in total for media production and national TV broadcasting.
  • The remaining balance of $120,000.00 is due on or before March 04, 2024, with all funds being paid in USD.
  • The term of the Agreement shall start September 1, 2023, and shall end February 29, 2024, unless terminated earlier.

InvestmentPitch Media Video Discusses Foremost Lithium and its Pending Acquisition of the Pegmatite-Hosting Lac Simard South Property within Sayona Mining’s Abitibi Hub of Lithium Projects in Quebec

Retrieved on: 
Thursday, August 31, 2023
Lithium, Quartz, CSE, Season, FSE, Snow, NAL, Acquisition, Mining, Piedmont Lithium, ESG

It lies within the area that Sayona refers to as its Abitibi Hub, which includes the Authier Lithium Project, the Tansim project and the restored NAL operation.

Key Points: 
  • It lies within the area that Sayona refers to as its Abitibi Hub, which includes the Authier Lithium Project, the Tansim project and the restored NAL operation.
  • Lac Simard South, with 24 pegmatites identified from satellite imagery, is easily accessible year-round by way of well-maintained roads with little overburden.
  • According to a report from 1980, the Lac Simard South property sampled 2.1% Lithium which is 4.52% Lithium Oxide and 5.88% Tantalum Oxide.
  • Not only is Lac Simard South property in an active lithium camp with large established resources, but we will be located near Sayona's lithium concentrators and refineries.

Victory Square Technologies Reports 2023 Q2 Financial Results

Retrieved on: 
Wednesday, August 30, 2023
Benchmark, Diamond, CSE, Augmented reality, Use, International, Bank statement, Victory Square, Prescription, NAV, Nursing, FSE, Pharmacy, Accounting, Documentation, Digital health, Investment, Patient, Physician, MD, Machine learning, OTC, SEDAR, Growth, Artificial intelligence, VST, Spice, Video game, Clothing, Security (finance), Satellite navigation device, Cryptocurrency, Tutoring, Risk management, Hospital, Blockchain

$4,937,216.84

Key Points: 
  • $4,937,216.84
    Unaudited NAV of approximately $78,681,041 as at June 30, 2023 (see Use of Non-GAAP Financial Measures)
    VANCOUVER, British Columbia, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Victory Square Technologies Inc. (“Victory Square” or the “Company”) (CSE:VST) (OTC:VSQTF) (FWB:6F6), a company that gives investor access to a portfolio of 25+ innovative companies from around the world in a single stock, announces it has filed its condensed interim consolidated financial statements and Interim Management Discussion and Analysis (MD&A) for the three- and six-month period ended June 30, 2023.
  • Victory Square is a Venture Builder that provides investors a liquid way to invest in early-stage technology companies without buying a venture fund that requires accredited investor status or multi-year commitments.
  • Second, our management team and advisors are actively involved in our investments from incubation through monetization, providing them with financial, operational, and strategic support to scale globally.
  • And, our goal is to continue to grow our NAV going forward,” Shafin Diamond Tejani, CEO of Victory Square.

Medigene presents rationale for combining its 3S TCRs with enhancement tools as an approach to improve clinical outcomes

Retrieved on: 
Wednesday, August 30, 2023
KRAS, E2E, CD28, FSE, TCR, Patient, Tumor microenvironment, Safety, Vaccine, Medical imaging

Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard) is an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors.

Key Points: 
  • Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard) is an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors.
  • Prof. Dolores Schendel, Medigene‘s Chief Scientific Officer, has been invited to present at the 8th CAR-TCR Summit in Boston on August 30, 2023.
  • “Medigene is committed to creating best-in-class, differentiated TCR-T therapies for multiple solid tumor indications that are optimized for both safety and efficacy.
  • For more details, please find the presentation on Medigene’s website: https://medigene.com/science/abstracts/

Mydecine Announces Conditional Approval of CSE Listing

Retrieved on: 
Wednesday, August 30, 2023
OTC, NEO Exchange, CSE, FSE, Canadian Securities Exchange, NEO, Security (finance)

VANCOUVER, British Columbia, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO:MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), is pleased to announce that it has made an application and received conditional approval to list its common shares on the Canadian Securities Exchange (the "CSE") subject to fulfilling customary CSE requirements.

Key Points: 
  • VANCOUVER, British Columbia, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO:MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), is pleased to announce that it has made an application and received conditional approval to list its common shares on the Canadian Securities Exchange (the "CSE") subject to fulfilling customary CSE requirements.
  • The Company anticipates that trading will commence immediately upon receipt of voluntarily delisting approval from the NEO Exchange with a trading date to be provided in due course.
  • The Company’s trading symbol “MYCO” will remain the same.
  • Management is of the view that listing the common shares on the CSE will provide the Company continued liquidity for its shareholders and it will allow the Company to continue to reduce expenses due to the CSE's lower operating costs.

Q2 Metals Resumes Exploration Work at Its Mia Lithium Property in James Bay, Quebec

Retrieved on: 
Wednesday, August 30, 2023
Lithium, Eeyou Istchee James Bay Regional Government, Wildfire, Q2, Mia, FSE, Forest, Collection, Natural Resources, Weather, Property

Vancouver, BC, Aug 30, 2023 - (ACN Newswire) - Q2 Metals Corp. (TSXV: QTWO) (OTCQB: QUEXF) (FSE: 458) ("Q2" or the "Company") is pleased to announce the resumption of its exploration activities at the Mia Lithium Property (the "Property") located in the Eeyou Istchee James Bay territory of Quebec.

Key Points: 
  • Vancouver, BC, Aug 30, 2023 - (ACN Newswire) - Q2 Metals Corp. (TSXV: QTWO) (OTCQB: QUEXF) (FSE: 458) ("Q2" or the "Company") is pleased to announce the resumption of its exploration activities at the Mia Lithium Property (the "Property") located in the Eeyou Istchee James Bay territory of Quebec.
  • With the restrictions lifted, the Q2 geology team has mobilized and will immediately continue surface mapping/prospecting and rock sampling.
  • The secondary objective will be to assess the potential of the broader trends on the Property (see Figure 1).
  • "We are excited to get back to the Mia Property to continue our field work," said Q2 President and Chief Executive Officer, Alicia Milne.